Hydroxyurea Can Reduce or Eliminate Transfusion Requirements in Children with Major and Intermediate Thalassemia
Journal Title: Iranian Journal of Blood and Cancer - Year 2009, Vol 1, Issue 4
Abstract
Background: Hydroxyurea (HU) is a well known chemotherapeutic agent that has been used largely for various myeloproliferative diseases over the past 20 years. In β-thalassemia, the effect of HU is much less clear and remains controversial. This study was undertaken to describe the hematologic and clinical responses of thalassemia major and intermediate patients to HU treatment during 2 years. Materials and Methods: Seventy one major and twenty transfusion-dependent intermediate thalassemia participants were selected among 150 β-thalassemia patients. All patients underwent laboratory tests, and the state of energy, social activity, tolerance, and mood were recorded in the beginning of the study. Echocardiography was carried out before and during treatment with HU. All patients were treated with HU the initial dose was 10- 15mg/kg/day given once a day. Results: All the patients tolerated HU well and showed a dramatic response to the drug. Nine of 20 intermediate and 8 of 71 major patients became completely transfusion free. In 6 intermediate and 15 major patients, transfusion interval prolonged more than 50%. After treatment, 95% of intermediate and 81% of major patients described an increase in social activity. HU therapy was also associated with a marked decrease in serum ferritin level in major thalassemia patients. Conclusion: HU may be administered in thalassemia major and intermediate patients to minimize or obviate the need for regular transfusion and concomitant iron overload. HU therapy appears to be safe and effective when administrated in thalassemia patients.
Authors and Affiliations
Azamsadat Hashemi, Mahboobeh Abrishamkar, Ali Reza Jenabzade, Ziae Eslami
Keywords
Related Articles
- EP ID EP382884
- DOI -
- Views 84
- Downloads 0
Evaluation of Leukoreduction in Packed Cell Units Filtered by Home-Made Bedside Filters: Pre and Post Revision of Product Technology and Materials According to Standard Values
Introduction: Leukocytes causing a wide variety of side effects after transfusion are present in all blood products prepared by standard methods. As a consequence, the use of filter technology for leukoreduction has been...
Peykan check, a simple continuous quality control method for hematology analyzers
A simple inexpensive con!nuous quality control method, by means of eight basic blood coun!ng parameters, obtained from automated hematology analyzers, using pa!ent samples, is described. A few samples with low, normal an...
Neutropenia Following Intravenous Immunoglobulin Therapy in Pediatric Patients with Idiopathic Thrombocytopenic Purpura
Background: Children with idiopathic thrombocytopenic purpura who are treated with intravenous immunoglobulin therapy might experience a decline in their absolute neutrophil count. The aim of this study was to investigat...
Case Series of Hepatoblastoma
Background: In the past 20 years, a dramatic improvement in the prognosis of patients with hepatoblastoma (HB) has been achieved by combining surgery and chemotherapy in several national and international trials. Materia...
Hyperimmunes Plasma Procurement and Products
This article has no abstract.